Antibodies against CXCR4 and methods of use thereof
The invention provides human monoclonal antibodies or fragments thereof, that specifically bind to CXCR4. Disclosed are methods of use of such antibodies for the treatment and/or prevention of a CXCR4 disease or disorder such as cancer and X4-tropic HIV-1 infection Also provided are methods of use of such antibodies and antibody fragments for the treatment or prevention of cancer metastasis. The invention provides methods of mobilizing CD34 + stem cells from the bone marrow and methods of blocking chemotaxis of CXCR4-expressing cells in response to SDF-1. Also provided are methods of use of the antibodies and fragments thereof for the prevention or treatment of graft-versus-host disease. Finally, the invention provides methods of inhibiting new tumor blood vessel formation and/or tumor cell angiogenesis.
1. A human monoclonal antibody or an scFv antibody, which binds to the chemokine receptor CXCR4 and has a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:29), WISAYNGNTNYAQKLQG (SEQ ID NO:30), and DTPGIAARRYYYYGMDV (SEQ ID NO:31), respectively, and a light chain with three CDRs comprising the amino acid sequences QGDSLRKFFAS (SEQ ID NO:32), GKNSRPS (SEQ ID NO:33), and NSRDSRDNHQV (SEQ ID NO:34), respectively.
2. The human monoclonal antibody or scFv antibody of claim 1 , wherein the monoclonal antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 12.
3. The human monoclonal antibody of claim 1 , wherein said monoclonal antibody blocks the function of SDF-1.
4. The scFv antibody of claim 1 , wherein said scFv antibody blocks the function of SDF-1.
5. A composition comprising the human monoclonal antibody or scFv antibody of claim 1 , and a carrier.
6. A kit comprising, in one or more containers, the composition of claim 5 .
7. A method of reducing X4-tropic HIV-1 infection, the method comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of the human monoclonal antibody of claim 1 , prior to the manifestation of symptoms characteristic of X4-tropic HIV-1 infection.
8. A fusion protein comprising an anti-CXCR4 antibody fragment fused to a human protamine protein or fragment thereof, wherein the anti-CXCR4 antibody fragment comprises
a.) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 4 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:12; or
b.) a heavy chain with three CDRs comprising the amino acid sequences SYGIS (SEQ ID NO:29), WISAYNGNTNYAQKLQG (SEQ ID NO:30), and
DTPGIAARRYYYYGMDV (SEQ ID NO:31) respectively and a light chain with three CDRs comprising the amino acid sequences QGDSLRKFFAS (SEQ ID NO:32),
GKNSRPS (SEQ ID NO:33), and NSRDSRDNHQV (SEQ ID NO:34) respectively; and
wherein said anti-CXCR4 antibody fragment specifically binds to a CXCR4-expressing cell and wherein said human protamine protein binds to an siRNA molecule.